文献速递肝病

肝ChREBP激活在糖原贮积病1a型小鼠模型中限制非酒精性脂肪肝发展

Hepatic Carbohydrate Response Element Binding Protein Activation Limits Nonalcoholic Fatty Liver Disease Development in a Mouse Model for Glycogen Storage Disease Type 1a.
PubMed 文献 · Hepatology · 2020-10-30

研究在肝特异性G6pc敲除的糖原贮积病1a型小鼠中,用AAV敲低肝ChREBP活性,发现ChREBP敲低加重肝大、增加糖原和脂质积累,机制涉及下调糖酵解和新生脂肪生成以及抑制VLDL-TG分泌。ChREBP通过诱导VLDL脂化蛋白MTTP和TM6SF2促进TG分泌,从而限制NAFLD发展。

要点

  • 肝ChREBP敲低加重GSD1a小鼠肝大和肝内糖原、脂质积累。
  • ChREBP敲低减少糖酵解和新生脂肪生成,同时强烈抑制VLDL脂化。
  • ChREBP通过诱导MTTP和TM6SF2促进VLDL-TG分泌,限制NAFLD发展。

核心结论

  • 在GSD1a小鼠肝脏中减弱ChREBP诱导会因糖酵解减少和VLDL-TG分泌受抑而进一步积累糖原和脂质,加重肝大。
  • ChREBP激活通过平衡肝脏TG生成与分泌来限制GSD1a中NAFLD的发展。

研究设计与样本

  • 研究使用肝特异性G6pc敲除(L-G6pc-/-)小鼠,以AAV2或AAV8递送抗ChREBP短发夹RNA,将肝ChREBP活性正常化至接受AAV8-scrambled shRNA的野生型小鼠水平。

主要发现

  • 肝ChREBP敲低显著增加L-G6pc-/-小鼠肝脏重量和肝细胞大小。
  • ChREBP敲低伴随肝内G6P、糖原和脂质积累,同时糖酵解和脂肪生成基因表达降低。
  • 酶活性、通量测定、肝代谢物分析和VLDL-TG分泌实验显示ChREBP敲低减少下游糖酵解和新生脂肪生成,并强烈抑制VLDL脂化,促进「旧脂肪」储存。
  • shSCR处理的L-G6pc-/-小鼠中VLDL-TG分泌增强,与ChREBP依赖的VLDL脂化蛋白MTTP和TM6SF2诱导相关,TM6SF2经ChIP-qPCR确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Glycogen storage disease (GSD) type 1a is an inborn error of metabolism caused by defective glucose-6-phosphatase catalytic subunit (G6PC) activity. Patients with GSD 1a exhibit severe hepatomegaly due to glycogen and triglyceride (TG) accumulation in the liver. We have shown that the activity of carbohydrate response element binding protein (ChREBP), a key regulator of glycolysis and de novo lipogenesis, is increased in GSD 1a. In the current study, we assessed the contribution of ChREBP to nonalcoholic fatty liver disease (NAFLD) development in a mouse model for hepatic GSD 1a. APPROACH AND RESULTS: Liver-specific G6pc-knockout (L-G6pc-/- ) mice were treated with adeno-associated viruses (AAVs) 2 or 8 directed against short hairpin ChREBP to normalize hepatic ChREBP activity to levels observed in wild-type mice receiving AAV8-scrambled short hairpin RNA (shSCR). Hepatic ChREBP knockdown markedly increased liver weight and hepatocyte size in L-G6pc-/- mice. This was associated with hepatic accumulation of G6P, glycogen, and lipids, whereas the expression of glycolytic and lipogenic genes was reduced. Enzyme activities, flux measurements, hepatic metabolite analysis and very low density lipoprotein (VLDL)-TG secretion assays revealed that hepatic ChREBP knockdown reduced downstream glycolysis and de novo lipogenesis but also strongly suppressed hepatic VLDL lipidation, hence promoting the storage of "old fat." Interestingly, enhanced VLDL-TG secretion in shSCR-treated L-G6pc-/- mice associated with a ChREBP-dependent induction of the VLDL lipidation proteins microsomal TG transfer protein and transmembrane 6 superfamily member 2 (TM6SF2), the latter being confirmed by ChIP-qPCR. CONCLUSIONS: Attenuation of hepatic ChREBP induction in GSD 1a liver aggravates hepatomegaly because of further accumulation of glycogen and lipids as a result of reduced glycolysis and suppressed VLDL-TG secretion. TM6SF2, critical for VLDL formation, was identified as a ChREBP target in mouse liver. Altogether, our data show that enhanced ChREBP activity limits NAFLD development in GSD 1a by balancing hepatic TG production and secretion.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Lei Y, Hoogerland JA, Bloks VW, et al. Hepatic Carbohydrate Response Element Binding Protein Activation Limits Nonalcoholic Fatty Liver Disease Development in a Mouse Model for Glycogen Storage Disease Type 1a. Hepatology. 2020. PMID: 32083759. doi:10.1002/hep.31198

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。